摘要
目的探讨氟替美维联合复方甲氧那明治疗老年慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的临床效果。方法回顾性分析2021年9月至2022年11月太仓市第一人民医院收治的82例老年慢性阻塞性肺疾病急性加重(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)经住院治疗达到稳定期患者的病历资料,将2021年9月至2022年4月接受复方甲氧那明治疗的40例患者作为对照组,2022年5~11月接受氟替美维联合复方甲氧那明治疗的42例患者作为观察组,比较两组治疗3个月后的总体疗效、病情改善程度、肺功能指标及用药安全性。结果经3个月治疗后,观察组总有效率95.24%(40/42)高于对照组80.00%(32/40),组间比较差异有统计学意义(P<0.05);观察组COPD患者自我评估测试问卷(COPD assessment test,CAT)、圣乔治呼吸问卷(St George’s respiratory questionnaire,SGRQ)评分低于对照组,组间比较差异有统计学意义(P<0.05);观察组第1秒呼气最大容积(forced expiratory volume in one second,FEV_(1))、呼气峰值流速(peak expiratory flow rate,PEFR)、FEV_(1)与用力肺活量比值(FEV_(1)/forced vital capacity,FEV_(1)/FVC)高于对照组,组间比较差异有统计学意义(P<0.05);观察组不良反应发生率16.67%(7/42),对照组12.50%(5/40),组间比较差异无统计学意义(P>0.05)。结论老年COPD患者接受氟替美维联合复方甲氧那明治疗,可提高疗效,促进病情转归,进一步改善肺功能,且未明显增加不良反应。
Objective To investigate the clinical effect of flutimevix combined with compound methoxyphenamine in the treatment of chronic obstructive pulmonary disease(COPD)in the elderly.Methods A retrospective analysis was performed for the data of 82 elderly patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)diagnosed and treated by Taicang First People's Hospital from September 2021 to November 2022 who reached stability after hospitalization,and 40 patients who received compound methoxyphenamine from September 2021 to April 2022 were used as the control group,and 42 patients who received flutimevit and compound methoxynamine in May to November 2022 were the observation group.The overall efficacy,disease degree,lung function indexes and medication safety of the two groups after 3 months of treatment were compared.Results After 3 months of treatment,the total effective rate of the observation group and the control group were 95.24%(40/42)and 80.00%(32/40),respectively,and the difference was statistically significant(P<0.05),and the self-assessment test(CAT)and St.George's breathing questionnaire(SGRQ)scores of COPD patients decreased significantly compared with the control group(P<0.05).The observed group had higher forced expiratory volume in one second(FEV_(1)),peak expiratory flow rate(PEFR),FEV_(1)/forced vital capacity(FEV_(1)/FVC)ratio than the control group,and the comparison between the groups was statistically significant(P<0.05).The incidence of adverse reactions was 16.67%(7/42)and 12.50%(5/40)in the observation group and control group,respectively,and the difference was not statistically significant(P>0.05).Conclusion Flutimecin combined with combined with methoxynamine in elderly patients with COPD can improve the efficacy,promote the prognosis,and further improve lung function,without significantly increasing adverse reactions.
作者
李响
LI Xiang(Department of Geriatrics,Taicang First People's Hospital(Taicang Hospital Affiliated to Soochow University),Taicang,Jiangsu 215400,China)
出处
《慢性病学杂志》
2023年第7期967-970,共4页
Chronic Pathematology Journal
关键词
慢性阻塞性肺疾病
联合用药
肺功能
Chronic obstructive pulmonary disease
Combination medications
Lung function
